Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 2
2006 4
2007 3
2008 2
2009 2
2010 4
2011 2
2012 1
2013 2
2014 3
2015 2
2016 1
2017 3
2018 1
2019 4
2020 2
2021 3
2022 5
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact.
Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, Davis Z, Rigolin GM, Visentin A, Xochelli A, Delgado J, Baran-Marszak F, Stalika E, Abrisqueta P, Durechova K, Papaioannou G, Eclache V, Dimou M, Iliakis T, Collado R, Doubek M, Calasanz MJ, Ruiz-Xiville N, Moreno C, Jarosova M, Leeksma AC, Panayiotidis P, Podgornik H, Cymbalista F, Anagnostopoulos A, Trentin L, Stavroyianni N, Davi F, Ghia P, Kater AP, Cuneo A, Pospisilova S, Espinet B, Athanasiadou A, Oscier D, Haferlach C, Stamatopoulos K; ERIC, the European Research Initiative on CLL. Baliakas P, et al. Among authors: baran marszak f. Blood. 2019 Mar 14;133(11):1205-1216. doi: 10.1182/blood-2018-09-873083. Epub 2019 Jan 2. Blood. 2019. PMID: 30602617 Free PMC article.
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
Mansouri L, Thorvaldsdottir B, Sutton LA, Karakatsoulis G, Meggendorfer M, Parker H, Nadeu F, Brieghel C, Laidou S, Moia R, Rossi D, Catherwood M, Kotaskova J, Delgado J, Rodríguez-Vicente AE, Benito R, Rigolin GM, Bonfiglio S, Scarfo L, Mattsson M, Davis Z, Gogia A, Rani L, Baliakas P, Foroughi-Asl H, Jylhä C, Skaftason A, Rapado I, Miras F, Martinez-Lopez J, de la Serna J, Rivas JMH, Thornton P, Larráyoz MJ, Calasanz MJ, Fésüs V, Mátrai Z, Bödör C, Smedby KE, Espinet B, Puiggros A, Gupta R, Bullinger L, Bosch F, Tazón-Vega B, Baran-Marszak F, Oscier D, Nguyen-Khac F, Zenz T, Terol MJ, Cuneo A, Hernández-Sánchez M, Pospisilova S, Mills K, Gaidano G, Niemann CU, Campo E, Strefford JC, Ghia P, Stamatopoulos K, Rosenquist R. Mansouri L, et al. Among authors: baran marszak f. Leukemia. 2023 Feb;37(2):339-347. doi: 10.1038/s41375-022-01802-y. Epub 2022 Dec 24. Leukemia. 2023. PMID: 36566271 Free PMC article.
Immuno-regulatory malignant B cells contribute to Chronic Lymphocytic Leukemia progression.
Mékinian A, Quinquenel A, Belkacem KA, Kanoun F, Dondi E, Franck E, Boubaya M, Mhibik M, Baran-Marszak F, Letestu R, Ajchenbaum-Cymbalista F, Lévy V, Varin-Blank N, Le Roy C. Mékinian A, et al. Among authors: baran marszak f. Cancer Gene Ther. 2023 Jul;30(7):1018-1028. doi: 10.1038/s41417-023-00602-5. Epub 2023 Mar 28. Cancer Gene Ther. 2023. PMID: 36973425 Free PMC article.
Impact of Low-Burden TP53 Mutations in the Management of CLL.
Lazarian G, Cymbalista F, Baran-Marszak F. Lazarian G, et al. Among authors: baran marszak f. Front Oncol. 2022 Feb 8;12:841630. doi: 10.3389/fonc.2022.841630. eCollection 2022. Front Oncol. 2022. PMID: 35211418 Free PMC article. Review.
Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.
Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T. Leroy B, et al. Among authors: baran marszak f. Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Cancer Res. 2017. PMID: 28254861 Free PMC article. Review.
Correction: Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.
Mansouri L, Thorvaldsdottir B, Sutton LA, Karakatsoulis G, Meggendorfer M, Parker H, Nadeu F, Brieghel C, Laidou S, Moia R, Rossi D, Catherwood M, Kotaskova J, Delgado J, Rodríguez-Vicente AE, Benito R, Rigolin GM, Bonfiglio S, Scarfo L, Mattsson M, Davis Z, Gogia A, Rani L, Baliakas P, Foroughi-Asl H, Jylhä C, Skaftason A, Rapado I, Miras F, Martinez-Lopez J, de la Serna J, Rivas JMH, Thornton P, Larráyoz MJ, Calasanz MJ, Fésüs V, Mátrai Z, Bödör C, Smedby KE, Espinet B, Puiggros A, Gupta R, Bullinger L, Bosch F, Tazón-Vega B, Baran-Marszak F, Oscier D, Nguyen-Khac F, Zenz T, Terol MJ, Cuneo A, Hernández-Sánchez M, Pospisilova S, Mills K, Gaidano G, Niemann CU, Campo E, Strefford JC, Ghia P, Stamatopoulos K, Rosenquist R. Mansouri L, et al. Among authors: baran marszak f. Leukemia. 2023 Feb;37(2):504. doi: 10.1038/s41375-023-01813-3. Leukemia. 2023. PMID: 36635392 Free PMC article. No abstract available.
TP53 mutations at codon 234 are associated with chlorambucil treatment in chronic lymphocytic leukemia.
Lazarian G, Theves F, Hormi M, Letestu R, Eclache V, Bidet A, Cornillet-Lefebvre P, Davi F, Delabesse E, Estienne MH, Etancelin P, Kosmider O, Laibe S, Lode L, Muller M, Nadal N, Naguib D, Pastoret C, Poulain S, Sujobert P, Veronese L, Imache S, Lefebvre V, Cymbalista F, Baran-Marszak F, Soussi T; French Innovative Leukemia Organisation (FILO). Lazarian G, et al. Among authors: baran marszak f. Am J Hematol. 2022 Apr;97(4):E159-E162. doi: 10.1002/ajh.26479. Epub 2022 Feb 1. Am J Hematol. 2022. PMID: 35083778 Free article. No abstract available.
A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation.
Lazarian G, Yin S, Ten Hacken E, Sewastianik T, Uduman M, Font-Tello A, Gohil SH, Li S, Kim E, Joyal H, Billington L, Witten E, Zheng M, Huang T, Severgnini M, Lefebvre V, Rassenti LZ, Gutierrez C, Georgopoulos K, Ott CJ, Wang L, Kipps TJ, Burger JA, Livak KJ, Neuberg DS, Baran-Marszak F, Cymbalista F, Carrasco RD, Wu CJ. Lazarian G, et al. Among authors: baran marszak f. Cancer Cell. 2021 Mar 8;39(3):380-393.e8. doi: 10.1016/j.ccell.2021.02.003. Cancer Cell. 2021. PMID: 33689703 Free PMC article.
51 results